Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have emerged as a beneficial treatment not only for diabetes but also for heart and kidney health.
While their safety profile has generally been favorable in clinical trials, little is known about their safety in diabetic patients with cancer.
A new study, to be presented at ASN Kidney Week 2023, sheds light on the risks associated with SGLT2i in this specific patient population.
The Dual Benefits of SGLT2 Inhibitors
SGLT2 inhibitors have demonstrated their effectiveness in managing blood sugar levels while offering additional advantages for heart and kidney function.
These benefits extend to patients with and without diabetes, making them a versatile treatment option.
The study in question examined the safety outcomes of SGLT2 inhibitors in patients dealing with both diabetes and cancer.
The research involved 3,872 individuals prescribed SGLT2 inhibitors and 3,189 individuals prescribed another diabetes medication known as glucagon-like peptide 1 receptor agonists (GLP-1 RA).
Study Findings
Diabetic Ketoacidosis Risk: Patients taking SGLT2 inhibitors faced a higher risk of developing diabetic ketoacidosis, a condition characterized by an accumulation of acids in the blood. This finding highlights a potential concern associated with these medications.
Fracture Risk: The study also revealed an increased risk of fractures in patients using SGLT2 inhibitors. This observation emphasizes the importance of monitoring bone health in this patient group.
Acute Kidney Injury: On a positive note, individuals treated with SGLT2 inhibitors experienced a lower risk of acute kidney injury, signifying a potential protective effect on kidney function.
Urinary Tract Infection: The research showed that SGLT2 inhibitors were associated with a reduced risk of urinary tract infections, indicating a potential benefit for urinary health.
Hypovolemia, Low Blood Pressure, Genital Infection: There were no significant differences in the incidence of hypovolemia (fluid loss), low blood pressure, or genital infection between the groups using SGLT2 inhibitors and GLP-1 RA.
Implications and Decision-Making
Lead author Dr. Aisha Shaikh from the Memorial Sloan Kettering Cancer Center emphasized the significance of these findings for both patients and physicians.
Understanding the safety outcomes of SGLT2 inhibitors in patients with diabetes and cancer can guide informed decisions regarding treatment choices.
Conclusion
While SGLT2 inhibitors offer multiple health benefits, including improved heart and kidney function, their safety profile in patients with diabetes and cancer requires careful consideration.
This study provides valuable insights that can inform healthcare professionals and patients alike, facilitating informed choices regarding the use of SGLT2 inhibitors in this specific population.
If you care about diabetes, please read studies about new way to achieve type 2 diabetes remission, and one avocado a day keeps diabetes at bay.
For more information about diabetes, please see recent studies about 5 dangerous signs you have diabetes-related eye disease, and results showing why pomegranate is super fruit for people with diabetes.
Follow us on Twitter for more articles about this topic.
Copyright © 2023 Knowridge Science Report. All rights reserved.
